Florida is poised to eliminate HIV treatment assistance for 16,000 individuals enrolled in its Ryan White AIDS Drug Assistance Program (ADAP), a move that health officials warn will have devastating consequences for patients and public health. The cuts, announced February 27, 2026, will impact half of the state’s 32,000 ADAP clients, potentially leaving thousands without access to life-saving medication.
The abrupt decision has drawn immediate condemnation from HIV advocacy groups and medical professionals. Dr. Anna K. Person, chair of the HIV Medicine Association (HIVMA), called the cuts a “public health disaster” and urged state leadership to reconsider. “HIV treatment disruptions of this magnitude will result in a public health disaster,” Dr. Person stated. “Florida must follow due process and work with health care professionals, people with HIV and the state legislature to address any funding challenges.”
The Ryan White HIV/AIDS Program, a federal program, provides a critical safety net for individuals living with HIV who lack sufficient health insurance or other means to afford their medications. The program funds a network of providers across the country, including 14 Ryan White Part B HIV care consortia in Florida, which advise on planning and prioritizing service needs. These consortia deliver comprehensive outpatient health and support services to people living with HIV within specific geographic areas.
The Central Florida HIV Planning Council (CFHPC), for example, oversees the Ryan White system of care for five counties: Orange, Osceola, Seminole, Lake, and Brevard. The CFHPC advises on the allocation of federal funds for the Ryan White HIV/AIDS Program Parts A & B and provides HIV prevention and care planning.
The Florida Department of Health funds these consortia, but the recent cuts to the ADAP program threaten to undermine their ability to provide essential services. Advocates fear the cuts will not only endanger the health of those currently receiving treatment but also contribute to a rise in new HIV diagnoses and increased healthcare costs as individuals develop complications from untreated HIV.
The cuts come as Florida faces budgetary constraints. However, critics argue that eliminating access to HIV treatment is a short-sighted approach that will ultimately prove more costly in the long run. Disrupting treatment can lead to viral resistance, requiring more expensive medications and increasing the risk of transmission.
The HIVMA has appealed to Florida’s leadership to withdraw the cuts, emphasizing the progress the state has made in responding to the HIV epidemic. The organization warns that this action risks reversing those gains and leaving many vulnerable individuals without access to care. As of March 2, 2026, the state has not responded to the appeals.
